BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32122464)

  • 21. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing.
    Wang LX; Li R; Yang G; Lim M; O'Hara A; Chu Y; Fox BA; Restifo NP; Urba WJ; Hu HM
    Cancer Res; 2005 Nov; 65(22):10569-77. PubMed ID: 16288050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion.
    Ng SSM; Nagy BA; Jensen SM; Hu X; Alicea C; Fox BA; Felber BK; Bergamaschi C; Pavlakis GN
    Clin Cancer Res; 2017 Jun; 23(11):2817-2830. PubMed ID: 27986749
    [No Abstract]   [Full Text] [Related]  

  • 23. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
    Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
    Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.
    Klebanoff CA; Finkelstein SE; Surman DR; Lichtman MK; Gattinoni L; Theoret MR; Grewal N; Spiess PJ; Antony PA; Palmer DC; Tagaya Y; Rosenberg SA; Waldmann TA; Restifo NP
    Proc Natl Acad Sci U S A; 2004 Feb; 101(7):1969-74. PubMed ID: 14762166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
    Antony PA; Piccirillo CA; Akpinarli A; Finkelstein SE; Speiss PJ; Surman DR; Palmer DC; Chan CC; Klebanoff CA; Overwijk WW; Rosenberg SA; Restifo NP
    J Immunol; 2005 Mar; 174(5):2591-601. PubMed ID: 15728465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model.
    Díaz-Montero CM; El Naggar S; Al Khami A; El Naggar R; Montero AJ; Cole DJ; Salem ML
    Cancer Immunol Immunother; 2008 Apr; 57(4):563-72. PubMed ID: 17726606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines.
    Ji Y; Wrzesinski C; Yu Z; Hu J; Gautam S; Hawk NV; Telford WG; Palmer DC; Franco Z; Sukumar M; Roychoudhuri R; Clever D; Klebanoff CA; Surh CD; Waldmann TA; Restifo NP; Gattinoni L
    Proc Natl Acad Sci U S A; 2015 Jan; 112(2):476-81. PubMed ID: 25548153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SOCS1 prevents potentially skin-reactive cytotoxic T lymphocytes from gaining the ability to cause inflammatory lesions.
    Rodriguez GM; D'Urbano D; Bobbala D; Chen XL; Yeganeh M; Ramanathan S; Ilangumaran S
    J Invest Dermatol; 2013 Aug; 133(8):2013-22. PubMed ID: 23443260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
    Winter H; Hu HM; McClain K; Urba WJ; Fox BA
    J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
    Zhang X; Niedermann G
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
    Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
    J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by
    Abu Eid R; Ahmad S; Lin Y; Webb M; Berrong Z; Shrimali R; Kumai T; Ananth S; Rodriguez PC; Celis E; Janik J; Mkrtichyan M; Khleif SN
    Cancer Res; 2017 Aug; 77(15):4135-4145. PubMed ID: 28615225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impaired gp100-Specific CD8(+) T-Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma Model.
    Mairhofer DG; Ortner D; Tripp CH; Schaffenrath S; Fleming V; Heger L; Komenda K; Reider D; Dudziak D; Chen S; Becker JC; Flacher V; Stoitzner P
    J Invest Dermatol; 2015 Nov; 135(11):2785-2793. PubMed ID: 26121214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.
    Hu Z; Xia J; Fan W; Wargo J; Yang YG
    Oncotarget; 2016 Feb; 7(6):6448-59. PubMed ID: 26824989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitochondrial arginase-2 is a cell‑autonomous regulator of CD8+ T cell function and antitumor efficacy.
    Martí i Líndez AA; Dunand-Sauthier I; Conti M; Gobet F; Núñez N; Hannich JT; Riezman H; Geiger R; Piersigilli A; Hahn K; Lemeille S; Becher B; De Smedt T; Hugues S; Reith W
    JCI Insight; 2019 Nov; 4(24):. PubMed ID: 31751318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Artificial Antigen-Presenting Cell Delivering 11 Immune Molecules Expands Tumor Antigen-Specific CTLs in
    Zhang L; Song S; Jin X; Wan X; Shahzad KA; Pei W; Zhao C; Shen C
    Cancer Immunol Res; 2019 Jul; 7(7):1188-1201. PubMed ID: 31113806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope.
    Schaer DA; Li Y; Merghoub T; Rizzuto GA; Shemesh A; Cohen AD; Li Y; Avogadri F; Toledo-Crow R; Houghton AN; Wolchok JD
    PLoS One; 2011; 6(6):e21214. PubMed ID: 21731676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.